On November 9, 2026 Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, reported financial results for the three and nine months ended September 30, 2026 and recent corporate updates.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Business Highlights
•
Heron generated total net revenue of $35.3 million in Q3 2026, compared to $38.2 million in Q3 2025 and $37.7 million in Q2 2026. Heron ended the third quarter with $23.4 million in cash, cash equivalents and short-term investments.
•
Acute Care franchise updates: Net revenue increased 22.5% year-over-year for the three months ended September 30, 2026 and increased 32.4% year-over-year for the nine months ended September 30, 2026. ZYNRELEF contributed $10.6 million and $31.9 million net revenue in the three and nine months ended September 30, 2026, respectively. APONVIE contributed $4.5 million and $12.2 million net revenue in the three and nine months ended September 30, 2026, respectively.
•
Oncology Supportive Care franchise updates: Net revenue was $20.1 million in the three months ended September 30, 2026 and $63.5 million in the nine months ended September 30, 2026. CINVANTI contributed $20.0 million and $62.3 million in the three and nine months ended September 30, 2026, respectively. Commercial sales of SUSTOL ceased on September 30, 2026.
•
Proposed asset sale: In a separate press release issued today, Heron and CorMedix Therapeutics ("CorMedix") announced that they have entered into a definitive asset purchase agreement under which CorMedix will acquire substantially all of the assets of Heron (the "Asset Sale"). The Asset Sale is subject to approval by Heron’s stockholders and other customary closing conditions. Additional information is available in that press release and in the Current Report on Form 8-K to be filed by Heron with the Securities and Exchange Commission ("SEC").
Financial Guidance for 2026
As previously announced, the Company withdrew its full-year 2026 financial guidance in August 2026. The Company is not providing financial guidance at this time.
Net Revenue Performance – Three Months Ended September 30
(in thousands)
(unaudited)
2026
2025
Dollar Change
Percentage Change
Acute Care
$ 15,128
$ 12,347
$ 2,781
22.5%
APONVIE
$ 4,530
$ 3,034
$ 1,496
49.3%
ZYNRELEF
$ 10,598
$ 9,313
$ 1,285
13.8%
Oncology
$ 20,122
$ 25,866
($ 5,744)
(22.2%)
CINVANTI
$ 19,970
$ 23,955
($ 3,985)
(16.6%)
SUSTOL
$ 152
$ 1,911
($ 1,759)
(92.0%)
Total Net Revenue
$ 35,250
$ 38,213
($ 2,963)
(7.8%)
Net Revenue Performance – Nine Months Ended September 30
(in thousands)
(unaudited)
2026
2025
Dollar Change
Percentage Change
Acute Care
$ 44,088
$ 33,300
$ 10,788
32.4%
APONVIE
$ 12,200
$ 7,758
$ 4,442
57.3%
ZYNRELEF
$ 31,888
$ 25,542
$ 6,346
24.8%
Oncology
$ 63,539
$ 81,016
($ 17,477)
(21.6%)
CINVANTI
$ 62,298
$ 73,841
($ 11,543)
(15.6%)
SUSTOL
$ 1,241
$ 7,175
($ 5,934)
(82.7%)
Total Net Revenue
$ 107,627
$ 114,316
($ 6,689)
(5.9%)
Conference Call and Webcast
Heron will not host a conference call or webcast in connection with its third quarter 2026 financial results.
About ZYNRELEF for Postoperative Pain
ZYNRELEF is the first and only extended-release dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam. ZYNRELEF is the first and only extended-release local anesthetic to demonstrate in Phase 3 studies significantly reduced pain and significantly increased proportion of patients requiring no opioids through the first 72 hours following surgery compared to bupivacaine solution, the current standard-of-care local anesthetic for postoperative pain control. ZYNRELEF was initially approved by the FDA in May 2021 for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty. In December 2021, the FDA approved an expansion of ZYNRELEF’s indication to include foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures. On January 23, 2024, the FDA approved ZYNRELEF for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures.
Please see full prescribing information, including Boxed Warning, at www.ZYNRELEF.com.
About APONVIE for Prevention of Postoperative Nausea and Vomiting (PONV)
APONVIE is a substance P/neurokinin 1 (NK1) Receptor Antagonist (RA), indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. Delivered via a 30-second IV push, APONVIE 32 mg was demonstrated to be bioequivalent to oral aprepitant 40 mg with rapid achievement of therapeutic drug levels. APONVIE is the same formulation as Heron’s approved drug product CINVANTI. APONVIE is supplied in a single-dose vial that delivers the full 32 mg dose for PONV. APONVIE was approved by the FDA in September 2022 and became commercially available in the U.S. on March 6, 2023.
Please see full prescribing information at www.APONVIE.com.
About CINVANTI for Chemotherapy Induced Nausea and Vomiting (CINV) Prevention
CINVANTI, in combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin as a single-dose regimen, delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen, and nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen. CINVANTI is an IV formulation of aprepitant, an NK1 RA. CINVANTI is the first IV formulation to directly deliver aprepitant, the active ingredient in EMEND capsules. Aprepitant (including its prodrug, fosaprepitant) is a single-agent NK1 RA to significantly reduce nausea and vomiting in both the acute phase (0–24 hours after chemotherapy) and the delayed phase (24–120 hours after chemotherapy). The FDA-approved dosing administration included in the U.S. prescribing information for CINVANTI include 100 mg or 130 mg administered as a 30-minute IV infusion or a 2-minute IV injection.
Please see full prescribing information at www.CINVANTI.com.
About SUSTOL for CINV Prevention
SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is an extended-release, injectable 5-hydroxytryptamine type 3 RA that utilizes Heron’s Biochronomer drug delivery technology to maintain therapeutic levels of granisetron for ≥5 days. The SUSTOL global Phase 3 development program was comprised of two, large, guideline-based clinical studies that evaluated SUSTOL’s efficacy and safety in more than 2,000 patients with cancer. SUSTOL’s efficacy in preventing nausea and vomiting was evaluated in both the acute phase (0–24 hours after chemotherapy) and delayed phase (24–120 hours after chemotherapy).
Please see full prescribing information at www.SUSTOL.com.
Commercial sales of SUSTOL ceased on September 30, 2026.
(Press release, Heron Therapeutics, NOV 9, 2026, View Source [SID1234674472])